1. Home
  2. DETX vs NRSN Comparison

DETX vs NRSN Comparison

Compare DETX & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Defense Holdings Ltd. Common Shares

DETX

Liberty Defense Holdings Ltd. Common Shares

N/A

Current Price

$2.16

Market Cap

14.8M

ML Signal

N/A

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$0.51

Market Cap

14.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DETX
NRSN
Founded
N/A
2017
Country
United States
Israel
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.8M
14.2M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
DETX
NRSN
Price
$2.16
$0.51
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
19.5K
238.8K
Earning Date
N/A
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$583.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.25
52 Week High
$4.25
$1.30

Technical Indicators

Market Signals
Indicator
DETX
NRSN
Relative Strength Index (RSI) 30.31 42.47
Support Level N/A $0.39
Resistance Level $4.13 $0.74
Average True Range (ATR) 0.40 0.06
MACD -0.07 0.01
Stochastic Oscillator 4.93 67.23

Price Performance

Historical Comparison
DETX
NRSN

About DETX Liberty Defense Holdings Ltd. Common Shares

Liberty Defense Holdings Ltd is engaged in the development and commercialization of security detection technologies such as airports, stadiums, schools, and more. The company's Hexwave product utilizes millimeter wave technology and Advanced 3D imaging to detect concealed threats. In addition to HEXWAVE, the company has licensed High-Definition Advanced Imaging Technology (HD-AIT) for body and shoe scanning. The Company operates through three distinct segments: Corporate, HEXWAVE, and Contract. The company generates the majority of its revenue from the Contract segment. Geographically, the company generates the majority of its revenue from the United States.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: